Reduced cytotoxic activity upon treatment of IFN-DCs with soluble rTRAIL-R2 receptor (Figure 2e) was also detected only in 3 of 6 glioblastoma cell lines tested (GB#7, GB#10 and GB#11) (median suppression, 21.0%) and in U87 cell line, which has been reported to belong to a group of TRAIL-sensitive tumor cells [22]. The gene discussed is IFNA1; the disease is neoplasm.